377 related articles for article (PubMed ID: 33841328)
1. Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.
Nakano-Tateno T; Lau KJ; Wang J; McMahon C; Kawakami Y; Tateno T; Araki T
Front Endocrinol (Lausanne); 2021; 12():624686. PubMed ID: 33841328
[TBL] [Abstract][Full Text] [Related]
2. Treatment Options for Gonadotroph Tumors: Current State and Perspectives.
Ilie MD; Raverot G
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32735647
[TBL] [Abstract][Full Text] [Related]
3. Therapy of aggressive pituitary tumors.
Colao A; Grasso LF; Pivonello R; Lombardi G
Expert Opin Pharmacother; 2011 Jul; 12(10):1561-70. PubMed ID: 21434849
[TBL] [Abstract][Full Text] [Related]
4. Aggressive prolactinomas: how to manage?
Lasolle H; Ilie MD; Raverot G
Pituitary; 2020 Feb; 23(1):70-77. PubMed ID: 31617128
[TBL] [Abstract][Full Text] [Related]
5. Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor.
Nakano-Tateno T; Satou M; Inoshita N; van Landeghem FKH; Easaw J; Mehta V; Tateno T; Chik CL
Endocr Pathol; 2021 Sep; 32(3):418-426. PubMed ID: 32833164
[TBL] [Abstract][Full Text] [Related]
6. Management of aggressive pituitary adenomas: current treatment strategies.
Buchfelder M
Pituitary; 2009; 12(3):256-60. PubMed ID: 19003540
[TBL] [Abstract][Full Text] [Related]
7. [Pituitary carcinomas and aggressive adenomas: an overview and new therapeutic options].
Maïza JC; Caron P
Ann Endocrinol (Paris); 2009 Sep; 70 Suppl 1():S12-9. PubMed ID: 19878763
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay.
Ishida A; Shichi H; Fukuoka H; Inoshita N; Ogawa W; Yamada S
Pituitary; 2022 Apr; 25(2):238-245. PubMed ID: 34773564
[TBL] [Abstract][Full Text] [Related]
9. Multimodal therapy in aggressive pituitary tumors.
Iglesias P; Magallón R; Mitjavila M; Rodríguez Berrocal V; Pian H; Díez JJ
Endocrinol Diabetes Nutr (Engl Ed); 2020; 67(7):469-485. PubMed ID: 31740190
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor.
Ceccato F; Lombardi G; Albiger N; Mazzai L; Pambuku A; Rolma G; Zagonel V; Scaroni C
Anticancer Drugs; 2019 Jun; 30(5):533-536. PubMed ID: 30986806
[TBL] [Abstract][Full Text] [Related]
11. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
12. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.
Burman P; Casar-Borota O; Perez-Rivas LG; Dekkers OM
J Clin Endocrinol Metab; 2023 Jun; 108(7):1585-1601. PubMed ID: 36856733
[TBL] [Abstract][Full Text] [Related]
13. Management of pituitary tumors.
Shimon I; Melmed S
Ann Intern Med; 1998 Sep; 129(6):472-83. PubMed ID: 9735086
[TBL] [Abstract][Full Text] [Related]
14. An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.
Alshaikh OM; Asa SL; Mete O; Ezzat S
Endocr Pathol; 2019 Jun; 30(2):118-127. PubMed ID: 30706322
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
Thearle MS; Freda PU; Bruce JN; Isaacson SR; Lee Y; Fine RL
Pituitary; 2011 Dec; 14(4):418-24. PubMed ID: 19960369
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
17. Medical therapy for non-functioning pituitary tumors-a critical approach.
Tampourlou M; Karapanou O; Vassiliadi DA; Tsagarakis S
Hormones (Athens); 2019 Jun; 18(2):117-126. PubMed ID: 30368687
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas.
Minniti G; Paolini S; Rea MLJ; Isidori A; Scaringi C; Russo I; Osti MF; Cavallo L; Esposito V
J Neurooncol; 2020 Aug; 149(1):123-130. PubMed ID: 32632895
[TBL] [Abstract][Full Text] [Related]
19. Refractory lactotroph adenomas.
Urwyler SA; Karavitaki N
Pituitary; 2023 Jun; 26(3):273-277. PubMed ID: 36928728
[TBL] [Abstract][Full Text] [Related]
20. [Aggressive and resistant-to-treatment pituitary tumors].
Cuny T; Chanson P
Ann Endocrinol (Paris); 2013 Oct; 74 Suppl 1():S3-12. PubMed ID: 24356289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]